# Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

> **NCT06264674** · PHASE3 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 827 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** CHF5993 200/6/12.5 μg pMDI HFA-152a
- **DRUG:** Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a

## Key facts

- **NCT ID:** NCT06264674
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-27
- **Primary completion:** 2025-02-18
- **Final completion:** 2025-02-24
- **Target enrollment:** 827 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06264674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06264674, "Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06264674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*